Microbot Medical Inc. (NASDAQ:MBOT) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Microbot Medical, with three buys, one hold and one sell among five analysts. The average 12-month price target is $6.375.
• Microbot Medical shares opened at $1.38, near their one-year low of $1.28 and below their 50-day and 200-day moving averages of $1.60 and $1.94, respectively.
• The company reported a quarterly loss of $0.08 per share, in line with estimates, while revenue of $0.24 million exceeded the $0.13 million consensus forecast. Institutional investors own 16.3% of the stock.

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $6.3750.

A number of brokerages have commented on MBOT. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a report on Wednesday, June 3rd. Zacks Research lowered Microbot Medical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a report on Wednesday, July 8th. HC Wainwright reaffirmed a "buy" rating on shares of Microbot Medical in a research report on Wednesday, August 19th. Finally, B. Riley Financial began coverage on shares of Microbot Medical in a research report on Friday, September 11th. They set a "buy" rating and a $4.00 price target for the company.

Microbot Medical Price Performance

Shares of NASDAQ MBOT opened at $1.38 on Wednesday. Microbot Medical has a 1-year low of $1.28 and a 1-year high of $3.74. The business has a 50-day moving average of $1.60 and a 200-day moving average of $1.94. The company has a market capitalization of $92.69 million, a price-to-earnings ratio of -5.75 and a beta of 1.03.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Research analysts expect that Microbot Medical will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Microbot Medical

A number of institutional investors have recently modified their holdings of MBOT. CTC Alternative Strategies Ltd. bought a new position in shares of Microbot Medical during the first quarter worth about $28,000. Private Advisor Group LLC acquired a new position in shares of Microbot Medical in the 1st quarter worth approximately $54,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Microbot Medical in the 4th quarter valued at approximately $65,000. Cetera Investment Advisers increased its holdings in shares of Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 13,099 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company's stock valued at $183,000 after acquiring an additional 71,560 shares in the last quarter. Institutional investors and hedge funds own 16.30% of the company's stock.

Microbot Medical Company Profile

Microbot Medical Inc is a medical-device company focused on developing robotic and computer-assisted technologies for minimally invasive vascular procedures. The company's primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use system designed to enable physicians to remotely control the navigation and positioning of guidewires and catheters during endovascular interventions.

LIBERTY is intended to support procedures involving the peripheral and coronary vasculature while potentially reducing physician exposure to radiation and improving procedural control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.